Dicerna Pharmaceuticals

About:

Dicerna Pharmaceuticals is a biotechnology company with a focus on the development of innovative treatments for rare inherited diseases.

Website: http://www.dicerna.com

Twitter/X: DicernaPharma

Top Investors: RA Capital Management, Eli Lilly, Deerfield, Cormorant Asset Management, EcoR1 Capital

Description:

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.